Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Clodronic Acid Disodium Salt
Therapeutic Area : Musculoskeletal
Study Phase : Phase II/ Phase III
Sponsor : Pharmaceutical Development and Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 16, 2024
Lead Product(s) : Clodronic Acid Disodium Salt
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II/ Phase III
Sponsor : Pharmaceutical Development and Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clodronic Acid Disodium Salt
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MAFTEST® adjuvant bisphosphonates therapy Bonefos, (clodronate disodium) result showed significant efficacy and reduce risk of death at 5 and 10 years by 26% and 23% respectively in early-stage (stage I-III) breast cancer patients compared with current ...
Product Name : Bonefos
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 14, 2022
Lead Product(s) : Clodronic Acid Disodium Salt
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable